

Thrombosis Research Group Core Publications 2021

1. Arnesen CAL, Veres K, Horvath-Puho E, Hansen JB, Sorensen HT, Braekkan SK. Estimated lifetime risk of venous thromboembolism in men and women in a Danish nationwide cohort: impact of competing risk of death. *Eur J Epidemiol*. 2021. 10.1007/s10654-021-00813-w.
2. Edvardsen MS, Hansen ES, Hindberg K, Morelli VM, Ueland T, Aukrust P, Braekkan SK, Evensen LH, Hansen JB. Combined effects of plasma von Willebrand factor and platelet measures on the risk of incident venous thromboembolism. *Blood*. 2021; **138**: 2269-77. 10.1182/blood.2021011494.
3. Edvardsen MS, Hindberg K, Hansen ES, Morelli VM, Ueland T, Aukrust P, Braekkan SK, Evensen LH, Hansen JB. Plasma levels of von Willebrand factor and future risk of incident venous thromboembolism. *Blood Adv*. 2021; **5**: 224-32. 10.1182/bloodadvances.2020003135.
4. Evensen LH, Arnesen CAL, Rosendaal FR, Gabrielsen ME, Brumpton BM, Hveem K, Hansen JB, Braekkan SK. The Risk of Venous Thromboembolism Attributed to Established Prothrombotic Genotypes. *Thromb Haemost*. 2021. 10.1055/a-1698-6717.
5. Evensen LH, Folsom AR, Pankow JS, Hansen JB, Allison MA, Cushman M, Lutsey PL. Hemostatic factors, inflammatory markers, and risk of incident venous thromboembolism: The Multi-Ethnic Study of Atherosclerosis. *J Thromb Haemost*. 2021; **19**: 1718-28. 10.1111/jth.15315.
6. Frischmuth T, Hindberg K, Aukrust P, Ueland T, Braekkan SK, Hansen JB, Morelli VM. Plasma Levels of Leptin and Risk of Future Incident Venous Thromboembolism. *Thromb Haemost*. 2021. 10.1055/s-0041-1732295.
7. Frischmuth T, Hindberg K, Gabrielsen ME, Brumpton B, Hveem K, Braekkan SK, Hansen JB, Morelli VM. Joint Effect of Multiple Prothrombotic Genotypes and Obesity on the Risk of Incident Venous Thromboembolism. *Thromb Haemost*. 2021. 10.1055/a-1497-9777.
8. Grimnes G, Bhoelan S, Hindberg K, Davids M, Nieuwdorp M, Mollnes TE, Michelsen AE, Ueland T, Braekkan SK, Hansen JB, Tichelaar V. Impact of a Vancomycin-Induced Shift of the Gut Microbiome in a Gram-Negative Direction on Plasma Factor VIII:C Levels: Results from a Randomized Controlled Trial. *Thromb Haemost*. 2021. 10.1055/s-0041-1733906.
9. Hansen ES, Rinde FB, Edvardsen MS, Hindberg K, Latysheva N, Aukrust P, Ueland T, Michelsen AE, Hansen JB, Braekkan SK, Morelli VM. Elevated plasma D-dimer levels are associated with risk of future incident venous thromboembolism. *Thromb Res*. 2021; **208**: 121-6. 10.1016/j.thromres.2021.10.020.
10. Johnsen HS, Braekkan SK, Morelli VM, Hansen JB. Platelet count and risk of major bleeding in venous thromboembolism. *Platelets*. 2021; **32**: 444-52. 10.1080/09537104.2020.1769052.
11. Jorgensen H, Horvath-Puho E, Laugesen K, Braekkan S, Hansen JB, Sorensen HT. Socioeconomic status and risk of incident venous thromboembolism. *J Thromb Haemost*. 2021; **19**: 3051-61. 10.1111/jth.15523.
12. Jorgensen H, Horvath-Puho E, Laugesen K, Braekkan S, Hansen JB, Sorensen HT. Risk of a permanent work-related disability pension after incident venous thromboembolism in Denmark: A population-based cohort study. *PLoS Med*. 2021; **18**: e1003770. 10.1371/journal.pmed.1003770.
13. Le Gal G, Carrier M, Castellucci LA, Cuker A, Hansen JB, Klok FA, Langlois NJ, Levy JH, Middeldorp S, Righini M, Walters S, Force ICT. Development and implementation of common data elements for venous thromboembolism research: on behalf of SSC Subcommittee on official

Communication from the SSC of the ISTH. *J Thromb Haemost.* 2021; **19**: 297-303. 10.1111/jth.15138.

14. Osterud B, Latysheva N, Schoergenhofer C, Jilma B, Hansen JB, Snir O. A rapid, sensitive, and specific assay to measure TF activity based on chromogenic determination of thrombin generation. *J Thromb Haemost.* 2021. 10.1111/jth.15606.
15. Paulsen B, Gran OV, Severinsen MT, Hammerstrom J, Kristensen SR, Cannegieter SC, Skille H, Tjonneland A, Rosendaal FR, Overvad K, Naess IA, Hansen JB, Braekkan SK. Association of smoking and cancer with the risk of venous thromboembolism: the Scandinavian Thrombosis and Cancer cohort. *Sci Rep.* 2021; **11**: 18752. 10.1038/s41598-021-98062-0.
16. Ramberg C, Hindberg K, Biedermann JS, Cannegieter SC, van der Meer FJ, Snir O, Leebeek FWG, Kruip M, Hansen JB, Lijfering WM. Rosuvastatin treatment decreases plasma procoagulant phospholipid activity after a VTE: A randomized controlled trial. *J Thromb Haemost.* 2021. 10.1111/jth.15626.
17. Ramberg C, Jamaly S, Latysheva N, Wilsgard L, Sovershaev T, Snir O, Hansen JB. A modified clot-based assay to measure negatively charged procoagulant phospholipids. *Sci Rep.* 2021; **11**: 9341. 10.1038/s41598-021-88835-y.
18. Ramberg C, Wilsgard L, Latysheva N, Braekkan SK, Hindberg K, Sovershaev T, Snir O, Hansen JB. Plasma procoagulant phospholipid clotting time and venous thromboembolism risk. *Res Pract Thromb Haemost.* 2021; **5**: e12640. 10.1002/rth2.12640.
19. Skille H, Paulsen B, Hveem K, Severinsen MT, Gabrielsen ME, Kristensen SR, Naess IA, Hindberg K, Tjonneland A, Braekkan SK, Hansen JB. Prothrombotic genotypes and risk of venous thromboembolism in occult cancer. *Thromb Res.* 2021; **205**: 17-23. 10.1016/j.thromres.2021.06.019.
20. Skjeflo EW, Braekkan SK, Ludviksen JK, Snir O, Hindberg K, Mollnes TE, Hansen JB. Elevated plasma concentration of complement factor C5 is associated with risk of future venous thromboembolism. *Blood.* 2021; **138**: 2129-37. 10.1182/blood.2021010822.